461 related articles for article (PubMed ID: 14592694)
21. Inclusion complexes of fluorofenidone with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin.
Wang S; Ding Y; Yao Y
Drug Dev Ind Pharm; 2009 Jul; 35(7):808-13. PubMed ID: 19337873
[TBL] [Abstract][Full Text] [Related]
22. Improvement in Solubility-Permeability Interplay of Psoralens from
Machado RD; Silva JCG; Silva LAD; Oliveira GAR; Lião LM; Lima EM; de Morais MC; da Conceição EC; Rezende KR
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889459
[TBL] [Abstract][Full Text] [Related]
23. Dissolution enhancement of cefdinir with hydroxypropyl-β-cyclodextrin.
Guo B; Zhong S; Li N; Li X; Yi J; Jin M
Drug Dev Ind Pharm; 2013 Nov; 39(11):1638-43. PubMed ID: 24087855
[TBL] [Abstract][Full Text] [Related]
24. Inclusion complexation of lorazepam with different cyclodextrins suitable for parenteral use.
Holvoet C; Vander Heyden Y; Plaizier-Vercammen J
Drug Dev Ind Pharm; 2005 Jul; 31(6):567-75. PubMed ID: 16109630
[TBL] [Abstract][Full Text] [Related]
25. Study on the inclusion complexes of cryptotanshinone with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin.
Li JF; Wei YX; Ding LH; Dong C
Spectrochim Acta A Mol Biomol Spectrosc; 2003 Oct; 59(12):2759-66. PubMed ID: 14499836
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the complexes of furosemide with 2-hydroxypropyl-beta-cyclodextrin and sulfobutyl ether-7-beta-cyclodextrin.
Spamer E; Müller DG; Wessels PL; Venter JP
Eur J Pharm Sci; 2002 Sep; 16(4-5):247-53. PubMed ID: 12208454
[TBL] [Abstract][Full Text] [Related]
27. Improved Aqueous Solubility and Antihypercholesterolemic Activity of Ezetimibe on Formulating with Hydroxypropyl-β-Cyclodextrin and Hydrophilic Auxiliary Substances.
Srivalli KM; Mishra B
AAPS PharmSciTech; 2016 Apr; 17(2):272-83. PubMed ID: 26077622
[TBL] [Abstract][Full Text] [Related]
28. Solubility and dissolution rate of progesterone-cyclodextrin-polymer systems.
Lahiani-Skiba M; Barbot C; Bounoure F; Joudieh S; Skiba M
Drug Dev Ind Pharm; 2006 Oct; 32(9):1043-58. PubMed ID: 17012117
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes.
Patel SG; Rajput SJ
AAPS PharmSciTech; 2009; 10(2):660-9. PubMed ID: 19459053
[TBL] [Abstract][Full Text] [Related]
30. Development of morin/hydroxypropyl-β-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects.
Lima BDS; Campos CA; da Silva Santos ACR; Santos VCN; Trindade GDGG; Shanmugam S; Pereira EWM; Marreto RN; Duarte MC; Almeida JRGDS; Quintans JSS; Quintans LJ; Araújo AAS
Food Chem Toxicol; 2019 Apr; 126():15-24. PubMed ID: 30738132
[TBL] [Abstract][Full Text] [Related]
31. Inclusion complexes of tea polyphenols with HP-β-cyclodextrin:Preparation, characterization, molecular docking, and antioxidant activity.
Zhong Y; Li W; Ran L; Hou R; Han P; Lu S; Wang Q; Zhao W; Zhu Y; Dong J
J Food Sci; 2020 Apr; 85(4):1105-1113. PubMed ID: 32175596
[TBL] [Abstract][Full Text] [Related]
32. pH-dependent complexation of hydroxypropyl-beta-cyclodextrin with chlorin e6: effect on solubility and aggregation in relation to photodynamic efficacy.
Paul S; Heng PW; Chan LW
J Pharm Pharmacol; 2016 Apr; 68(4):439-49. PubMed ID: 26946047
[TBL] [Abstract][Full Text] [Related]
33. Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-β-cyclodextrin.
Liu M; Cao W; Sun Y; He Z
Int J Pharm; 2014 Dec; 477(1-2):159-66. PubMed ID: 25455768
[TBL] [Abstract][Full Text] [Related]
34. The physicochemical characteristics of freeze-dried scutellarin-cyclodextrin tetracomponent complexes.
Cao F; Guo J; Ping Q
Drug Dev Ind Pharm; 2005 Sep; 31(8):747-56. PubMed ID: 16221609
[TBL] [Abstract][Full Text] [Related]
35. Solubilization of a naphthoquinone derivative by hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and polyvinylpyrrolidone (PVP-K30). The influence of PVP-K30 and pH on solubilizing effect of HP-beta-CD.
Granero G; de Bertorello MM; Longhi M
Boll Chim Farm; 2002; 141(1):63-6. PubMed ID: 12064060
[TBL] [Abstract][Full Text] [Related]
36. Preparation, characterization and in vitro cytotoxicity study of dronedarone hydrochloride inclusion complexes.
Marcolino AIP; Macedo LB; Nogueira-Librelotto DR; Fernandes JR; Bender CR; Wust KM; Frizzo CP; Mitjans M; Vinardell MP; Rolim CMB
Mater Sci Eng C Mater Biol Appl; 2019 Jul; 100():48-61. PubMed ID: 30948084
[TBL] [Abstract][Full Text] [Related]
37. Physicochemical characterization and in vitro biological evaluation of solid compounds from furazolidone-based cyclodextrins for use as leishmanicidal agents.
Carvalho SG; Cipriano DF; de Freitas JCC; Junior MÂS; Ocaris ERY; Teles CBG; de Jesus Gouveia A; Rodrigues RP; Zanini MS; Villanova JCO
Drug Deliv Transl Res; 2020 Dec; 10(6):1788-1809. PubMed ID: 32803562
[TBL] [Abstract][Full Text] [Related]
38. Curve-fitting FTIR studies of loratadine/hydroxypropyl-beta-cyclodextrin inclusion complex induced by co-grinding process.
Lin SY; Hsu CH; Sheu MT
J Pharm Biomed Anal; 2010 Nov; 53(3):799-803. PubMed ID: 20619996
[TBL] [Abstract][Full Text] [Related]
39. Inclusion complexation of nimesulide with beta-cyclodextrins.
Vavia PR; Adhage NA
Drug Dev Ind Pharm; 1999 Apr; 25(4):543-5. PubMed ID: 10194611
[TBL] [Abstract][Full Text] [Related]
40. Elucidation of the orientation of selected drugs with 2-hydroxylpropyl-β-cyclodextrin using 2D-NMR spectroscopy and molecular modeling.
Adhikari S; Daftardar S; Fratev F; Rivera M; Sirimulla S; Alexander K; Boddu SHS
Int J Pharm; 2018 Jul; 545(1-2):357-365. PubMed ID: 29747001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
